• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

    12/2/20 8:00:00 AM ET
    $SNY
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email

    CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function.

    “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust preclinical portfolio and our novel discovery and drug development platform,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Wave is growing and having Jonathan at the helm of our HR function, as well as on our leadership team, will ensure that we continue to build a world-class organization, scale smartly, and maintain Wave’s special culture.”

    Mr. Rosin joins Wave with more than 25 years of experience in human resources, organization development, talent strategy, and leadership and team development. Prior to joining Wave, Mr. Rosin spent seven years as CHRO at Ironwood Pharmaceuticals where he served as a member of the executive operating committee. During his tenure at Ironwood, he was instrumental in building organizational capabilities and shaping the culture to support the company’s transition into a fully integrated biotechnology company, and continuously sought to upgrade Ironwood’s capabilities and focus on execution. Prior to joining Ironwood, he held human resources roles of increasing responsibility at Sanofi Genzyme and Fidelity Investments, among others. He has also consulted globally across industries as well as with multiple biotechnology companies to help build high-performing teams and to provide leadership coaching.

    “I am thrilled to be joining Wave at such an exciting and promising time, and to have the opportunity to partner with this exceptional team and individuals across the company,” said Mr. Rosin. “It is clear to me that Wave has developed and nurtured a unique and compelling culture that values innovation, inclusion, and making an impact on behalf of patients. I look forward to working with the team to continue transforming Wave’s vision into reality.”

    In connection with Mr. Rosin joining Wave, he received a share option award to purchase 53,000 ordinary shares of Wave and 27,000 restricted share units (RSU). The option and RSU were approved by Wave’s Compensation Committee and were granted to Mr. Rosin on December 1, 2020 outside of the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended, as an inducement material to Mr. Rosin’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $8.95 per share, the closing price on the grant date, and vests over four years with 25% vesting on December 1, 2021 and the remainder vesting in equal quarterly installments over the following three years. The RSU vests over four years in equal annual installments beginning on the first anniversary of the grant date.

    About Wave Life Sciences
    Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Mr. Rosin’s leadership and human resources experience guiding the company as it advances its clinical trials, preclinical portfolio and discovery and drug development platform; and beliefs that Mr. Rosin’s ability will help the growth of the company and its culture. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those discussed in these statements. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

    Investor Contact:
    Graham Morrell
    781-686-9600
    [email protected]

    Media Contact:
    Alicia Suter
    617-949-4817
    [email protected]


    Get the next $SNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNY
    $WVE

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    10/20/2025$18.00Overweight
    Wells Fargo
    Sanofi
    $SNY
    9/8/2025$58.00Equal-Weight → Overweight
    Morgan Stanley
    Sanofi
    $SNY
    9/2/2025Hold → Buy
    Deutsche Bank
    Sanofi
    $SNY
    8/8/2025Neutral → Overweight
    Analyst
    Wave Life Sciences Ltd.
    $WVE
    8/4/2025$19.00Buy
    Canaccord Genuity
    Wave Life Sciences Ltd.
    $WVE
    7/28/2025$24.00Outperform
    Oppenheimer
    Wave Life Sciences Ltd.
    $WVE
    7/16/2025$16.00Buy
    Citigroup
    Wave Life Sciences Ltd.
    $WVE
    6/11/2025$14.00Outperform
    Raymond James
    More analyst ratings

    $SNY
    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- Sanofi-Aventis Canada Inc./

    In the news release, Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose, issued 21-Oct-2025 by Sanofi-Aventis Canada Inc. over CNW, a footnote "*The standard-dose influenza vaccines used in the FLUNITY-HD study were VaxigripTetra (Sanofi) and InfluvacTetra (Viatris). Standard-dose vaccines often serve as the primary influenza prevention option for the general population" was missed in the original release and is now added at the end of the release. The complete, corrected release follows: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

    10/21/25 1:52:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

    Compared to standard-dose influenza vaccines, Fluzone High-Dose Influenza Vaccine demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p<0.001) in adults 65 years and overResults come from FLUNITY-HD, the largest influenza vaccine effectiveness study of individually randomized older adults, involving nearly half a million participants across several seasons and two geographic areas.Fluzone High-Dose also provided superior protection, compared to standard-dose influenza vaccines*, against hospitalizations due to pneumonia/influenza, hospitalizations caused by cardio-respiratory events, and all-cause hospitalizations in older

    10/21/25 1:52:00 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi

    CHICAGO, Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a Collaboration and License Agreement with Sanofi, an R&D driven, AI-powered biopharma company, committed to improving people's lives and delivering compelling growth. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY EVOQ's proprietary breakthrough NanoDisc technology restores the body's natural immune tolerance pathways and opens the door for a wide range of disease-specific, curat

    10/16/25 6:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    10/1/24 5:54:39 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    1/30/24 4:39:08 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

    4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

    1/17/24 7:06:57 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    SEC Filings

    View All

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    10/15/25 12:07:29 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Sanofi

    6-K - Sanofi (0001121404) (Filer)

    9/26/25 9:41:22 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    9/24/25 8:30:22 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Wave Life Sciences with a new price target

    Wells Fargo initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $18.00

    10/20/25 8:06:13 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Sanofi from Equal-Weight to Overweight and set a new price target of $58.00

    9/8/25 8:38:18 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi upgraded by Deutsche Bank

    Deutsche Bank upgraded Sanofi from Hold to Buy

    9/2/25 8:23:14 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

    For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

    3/28/25 10:17:55 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

    For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

    2/14/25 3:00:13 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

    Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

    11/4/24 4:49:34 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Bolno Paul sold $2,194,810 worth of Ordinary Shares (217,351 units at $10.10), decreasing direct ownership by 64% to 121,000 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    8/26/25 9:40:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Verdine Gregory L. sold $100,000 worth of Ordinary Shares (10,000 units at $10.00), decreasing direct ownership by 3% to 285,217 units (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    8/26/25 9:40:05 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tan Aik Na exercised 21,000 units of Ordinary Shares at a strike of $9.13 and sold $194,250 worth of Ordinary Shares (21,000 units at $9.25) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    8/19/25 8:00:04 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

    Initiative spans an IVD assay and a new Revvity Omics lab-developed test to expand clinical testing for early-stage disease screening Revvity, Inc. (NYSE:RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (NASDAQ:SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Early detection of T1D enables options for patients and caregivers to improve outcome

    10/2/25 8:00:00 AM ET
    $RVTY
    $SNY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

    Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)  First-ever demonstration of therapeutically restored physiological serum AAT production in a Pi*ZZ individual during a non-drug related acute phase response (20.6 µM total AAT, 10.3 µM M-AAT) Single dose of 400 mg achieved 12.8 µM total AAT and 5.3 µM M-AAT; ongoing 400 mg multidose cohort has potential to deliver further increases in serum AAT Data from 200 mg and 400 mg cohorts support monthly or less frequent subcutaneous dosing; 400 mg monthly multidose cohort data expected in 1Q 2026 WVE-0

    9/3/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

    WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 WVE-007, an INHBE GalNAc-siRNA designed to induce fat loss with muscle preservation, dosing is complete in expanded Cohort 2 (240 mg; from 8 to 32 individuals) of INLIGHT trial at dose predict

    7/30/25 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sanofi

    SC 13G/A - Sanofi (0001121404) (Subject)

    11/7/24 2:49:36 PM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNY
    $WVE
    Leadership Updates

    Live Leadership Updates

    View All

    ITM Appoints Annette Breunig as Chief People Officer

    Global HR leader to drive ITM's long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief People Officer (CPO). Ms. Breunig brings over 25 years of HR leadership experience at international pharmaceutical, manufacturing and technology companies, including at Siemens AG (FRA: SIE) and Sanofi (NASDAQ:SNY). At ITM, Ms. Breunig will lead the HR team in shaping strategies that unify the organization to achieve both team and business growth objectives while empowering em

    10/13/25 5:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

    TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

    6/9/25 10:00:00 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care